Entering the spotlight: hepatitis B surface antigen–specific B cells
Christoph Neumann-Haefelin and Robert Thimme
First published September 17, 2018 - More info
Related articles:
PD-1 blockade partially recovers dysfunctional virus–specific B cells in chronic hepatitis B infection
Loghman Salimzadeh, … , Patrick T.F. Kennedy, Antonio Bertoletti
Categories: Research Article Hepatology Infectious disease
Circulating and intrahepatic antiviral B cells are defective in hepatitis B
Alice R. Burton, … , Nadege Pelletier, Mala K. Maini
Categories: Research Article Immunology Infectious disease
Abstract
Hepatitis B virus–specific (HBV-specific) T cells have been identified as main effector cells in HBV clearance. In contrast, B cells producing neutralizing antibodies against the HBV surface antigen (HBsAg) have been studied in little detail, mainly due to methodical limitations. In this issue of the JCI, two reports use a new technique to specifically detect and characterize HBsAg-specific B cells ex vivo. Indeed, these cells are present, but show phenotypic alterations and impaired function during acute and chronic HBV infection. Thus, HBsAg-specific B cells are a novel attractive target for antiviral strategies toward functional cure of chronic HBV infection.
Hepatitis B surface antibody in history and treatment
A fourth of the world’s population has been infected with hepatitis B virus (HBV), and an estimated 250 million people are chronically infected, putting them at risk for progressive liver disease, liver cirrhosis, liver failure, and hepatocellular carcinoma. Of adults infected with HBV, 95% clear the virus spontaneously, while 90% of newborns develop chronic infection. Since HBV infection does not induce an interferon response, HBV is a stealth virus with respect to the innate immune system (1, 2). Therefore, HBV clearance depends on a successful adaptive immune response. Indeed, a multispecific and vigorous HBV-specific CD8+ T cell response has been associated with viral clearance (3, 4), while HBV-specific CD8+ T cell exhaustion is a hallmark of persistent infection (5–7). Less attention, however, has been paid to the role of neutralizing antibodies targeting the envelope protein of HBV, the HBV surface antigen (HBsAg). Indeed, the hepatitis B surface antibody (anti-HBs) is only detectable in the blood of HBV-infected individuals after the loss of HBsAg, either upon the resolution of acute infection or in case of the rare event of spontaneous or drug-induced clearance of chronic HBV infection. Thus, anti-HBs is seen as not playing a major role in HBV clearance. Anti-HBs, on the other hand, has been established as a diagnostic tool, indicating protective immunity after acute-resolving HBV infection or vaccination as well as “functional cure” of chronic HBV infection (HBsAg to anti-HBs seroconversion). There are, however, several clinical observations that argue against such a minor role of anti-HBs. First, anti-HBs contained in hepatitis B immunoglobulin (HBIG) is well known to prevent vertical HBV transmission from infected mothers to newborns as well as reinfection of liver transplants in previously HBV-infected hosts. Second, B cell–depleting drugs used in oncology and rheumatology, such as the anti-CD20 antibody rituximab, induce HBV reactivation in HBV carriers and even in patients with “resolved” HBV in whom nuclear HBV cccDNA persists as a viral reservoir for decades (8). These clinical observations indicate that anti-HBs has a more prominent role than previously acknowledged. Indeed, anti-HBs can block HBV cell entry, either by blocking the binding site of HBsAg for the cell receptor recently identified to be sodium taurocholate cotransporting polypeptide (NTCP) or by binding to the “antigenic loop” of HBsAg that is involved in interaction with heparan sulfate proteoglycan (HSPG) in a prereceptor step of cell entry. In addition to direct inhibition of cell entry, anti-HBs also mediate endocytosis and subsequent neutralization of virions as well as Fc-mediated phagocytosis and killing of infected cells. In addition, anti-HBs, HBsAg, and additional components build immune complexes that can activate HBV-specific T cells (9).作者: StephenW 时间: 2018-10-2 16:38
进入聚光灯:乙型肝炎表面抗原特异性B细胞
Christoph Neumann-Haefelin和Robert Thimme
首次发布于2018年9月17日 - 更多信息
相关文章:
PD-1阻断部分恢复慢性乙型肝炎感染中功能失调的病毒特异性B细胞
Loghman Salimzadeh,......,Patrick T.F.肯尼迪,安东尼奥贝托莱蒂
分类:研究论文肝病学传染病
循环和肝内抗病毒B细胞在乙型肝炎中有缺陷
Alice R. Burton,......,Nadege Pelletier,Mala K. Maini
分类:研究文章免疫学传染病
HBsAg-specific B cells in acute and chronic HBV infection
Given these important antiviral functions of anti-HBs, a main open issue in HBV immunobiology is the reason for the lack of detectable anti-HBs in both acute and chronic HBV infection prior to HBsAg loss. To date, two plausible hypothetical explanations for the lack of anti-HBs have been put forth. First, it was suggested that anti-HBs is produced by HBsAg-specific B cells in acute and chronic HBV infection, but is depleted by the large number of circulating HBsAg-containing subviral particles that outnumber complete virions by an order of magnitude. This hypothesis was supported by the finding that complexes of anti-HBs with circulating HBsAg are not recognized by current diagnostic assays, but can be detected in chronically infected patients using highly sensitive immunoassays (10). Additionally, there were early and have been more recent reports of HBsAg-specific B cell dysfunction, especially in chronic HBV infection. Indeed, B cells isolated from patients with chronic HBV infection showed a reduced proliferative capacity and were not able to produce anti-HBs upon stimulation. This functional defect reverted after the rare event of HBsAg loss during chronic infection (11, 12). In the current issue of the JCI, Salimzadeh and Le Bert et al. from the Bertoletti laboratory (13) and Burton et al. from the Maini laboratory (14) addressed the issue of lack of anti-HBs during acute and chronic HBV infection by making use of a new technique to detect HBsAg-specific B cells. Specifically, they utilized fluorochrome-labeled recombinant HBsAg as “bait” to detect and characterize HBsAg-specific B cells by FACS analysis ex vivo. Strikingly, by using a similar approach independently, the two groups came to the very same results (Figure 1): first, HBsAg-specific B cells are present in acute, chronic, and resolved HBV infection in similar frequencies. Second, HBsAg-specific B cells isolated from patients with acute as well as chronic, but not resolved, HBV infection are unable to mature into anti-HBs–secreting cells in vitro. Third, in phenotypical analyses, these HBsAg-specific B cells in acute and chronic HBV infection resemble “atypical memory B cells” that are characterized by low expression of CD21 and CD27, but high expression of inhibitory markers, such as PD-1, and the transcription factor T-bet (15). Fourth, Burton et al. demonstrated that these HBsAg-specific atypical memory B cells accumulate in the liver, the site of infection and inflammation of HBV-infected patients. Fifth, this phenotype and functional impairment are not restricted to HBsAg-specific B cells, but also affect the global B cell population in HBV-infected patients, a finding with so far unclear implications that needs further clarification. Sixth, the function of HBsAg-specific B cells can be partially restored in vitro by specific culture conditions, such as PD-1 blockade (13, 14) or the addition of IL-2, IL-21, and CD40 ligand–expressing (CD40L-expressing) feeder cells (13). 作者: StephenW 时间: 2018-10-2 16:40